Skip to main content
Article thumbnail
Location of Repository

A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting

By Mark A Ware1, Paul Daeninck and Vincent Maida


Chemotherapy-induced nausea and vomiting (CINV) in cancer patients places a significant burden on patients’ function and quality of life, their families and caregivers, and healthcare providers. Despite the advances in preventing CINV, a substantial proportion of patients experience persistent nausea and vomiting. Nabilone, a cannabinoid, recently received Food and Drug Administration approval for the treatment of the nausea and vomiting in patients receiving cancer chemotherapy who fail to achieve adequate relief from conventional treatments. The cannabinoids exert antiemetic effects via agonism of cannabinoid receptors (CB1 and CB2). Clinical trials have demonstrated the benefits of nabilone in cancer chemotherapy patients. Use of the agent is optimized with judicious dosing and selection of patients

Topics: Review
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles


    1. (2001). (THC) interferes with conditioned retching in Suncus murinus: an animal model of anticipatory nausea and vomiting (ANV).
    2. (2005). [package insert].
    3. (1985). A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy.
    4. (1987). A double-blind randomised cross-over comparison of nabilone and metoclopramide in the control of radiation-induced nausea.
    5. (2002). A molecular basis of the therapeutic and psychoactive properties of cannabis (D9-tetrahydrocannabinol). Prog Neuro-Psychopharmacol Biol Psychiatry,
    6. (2005). A physician’s guide to pain and symptom management in cancer patients. 2nd ed.
    7. (1988). A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues.
    8. (1989). Advances in the management of nausea and vomiting induced by non-cisplatin containing chemotherapeutic regimens. Blood Rev,
    9. (2006). American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update
    10. (1984). An initial evaluation of nabilone in the control of radiotherapy-induced nausea and vomiting. Clin Radiol,
    11. (1983). Anti-emetic effi cacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy.
    12. (2003). Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev,
    13. (1998). Anticipatory nausea and vomiting in the era of 5-HT3 antiemetics. Support Care Cancer,
    14. (2005). Anticipatory nausea and vomiting. Support Care Cancer,
    15. (1993). Anticipatory nausea in cancer patients receiving chemotherapy: classical conditioning etiology and therapeutical implications.
    16. (1987). Antiemetic effi cacy of nabilone and dexamethasone: a randomized study of patients with lung cancer receiving chemotherapy.
    17. (2001). Cannabinoids for control of chemotherapy-induced nausea and vomiting: quantitative systematic review.
    18. (2006). Cannabinoids in medicine: a review of their therapeutic potential.
    19. (2001). Central neurocircuitry associated with emesis.
    20. (2006). Chemotherapy-induced nausea and vomiting: state of the art in
    21. (2005). Chemotherapy-induced nausea/ vomiting and functional status in women treated for breast cancer. Cancer Nurs,
    22. (1995). Clinical effi cacy of lorazepam in prophylaxis of anticipatory acute and delayed nausea and vomiting induced by high doses of cisplatin. A prospective randomized trial.
    23. (1975). Clinical pharmacology of nabilone, a cannabinol derivative. Clin Pharm Ther,
    24. (1986). Crossover comparison of the antiemetic effi cacy of nabilone and alizapride in patients with nonseminomatous testicular cancer receiving cisplatin therapy. Klin Wochenschr,
    25. (2006). Delta-9-tetrahydrocannabinol and cannabidiol, but not ondansetron, interfere with conditioned retching reactions elicited by a lithium-paired context in Suncus murinus: An animal model of anticipatory nausea and vomiting. Physiol Behav,
    26. (2007). Effi cacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin,
    27. (2004). Endocannabinoid-mediated short-term synaptic plasticity: depolarization-induced suppression of inhibition (DSI) and depolarization-induced suppression of excitation (DSE).
    28. (2005). Endocannabinoids and food intake: Newborn suckling and appetite regulation in adulthood. Exp Biol Med,
    29. (1990). Evolution and current status of pain programs. J Pain Symptom Manage,
    30. (2006). Experience with the synthetic cannabinoid in chronic noncancer pain. Pain Med,
    31. (2006). Exposure to a lithium-paired context elicits gapin in rats: A model of anticipatory nausea.
    32. (2006). FDA approvals: Lumigan, Cesamet, Omnitrope. Medscape Medical News.
    33. Importance of nausea.
    34. (1979). Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomized trial of antiemetics.
    35. (1988). Inhalation marijuana as an antiemetic for cancer chemotherapy.
    36. (2004). Initial experiences with medicinal extracts of cannabis for chronic pain: Results from 34 ’N of 1' studies.
    37. (2002). International union of pharmacology. XXVII. Classifi cation of cannabinoid receptors. Pharmacol Rev,
    38. (2006). Low dose treatment with the synthetic cannabinoid nabilone signifi cantly reduces spasticity-related pain. A double-blind placebo-controlled cross-over trial.
    39. (2001). Marijuana as Medicine.
    40. (2004). Mechanism of action of cannabinoids: how it may lead to treatment of cachexia, emesis, and pain.
    41. (2001). Medicinal use of cannabis: history and current status. Pain Res Manage,
    42. (2001). Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci,
    43. (1986). Nabilone and metoclopramide in the treatment of nausea and vomiting due to cisplatinum: a double blind study. Med Oncol Tumor Pharmacother,
    44. (1977). Nabilone: a potent antiemetic cannabinol with minimal euphoria.
    45. (1981). Nabilone: An effective antiemetic in patients receiving cancer chemotherapy.
    46. (1985). Nabilone. A preliminary review of its pharmacological properties and therapeutic use.
    47. (2003). Nausea and emesis remain signifi cant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics.
    48. (2000). Nausea and vomiting remain a signifi cant clinical problem:
    49. (1998). Neuropharmacology of emesis and its relevance to anti-emetic therapy. Consensus and controversies. Support Care Cancer,
    50. (2003). on behalf of the Aprepitant Protocol 054 Study Group.
    51. (2003). Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting – two new agents.
    52. (2005). Practical management of chemotherapy-induced nausea and vomiting.
    53. (2005). Preclinical science regarding cannabinoids as analgesics: an overview. Pain Res Manage, 10(suppl A):7A-14A.
    54. (2005). Preventing chemotherapyinduced nausea and vomiting: the economic implications of choosing antiemetics.
    55. (1986). Prospective randomized doubleblind trial of nabilone versus domperidone in the treatment of cytotoxicinduced emesis.
    56. (2004). Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer,
    57. (2003). Role of endogenous cannabinoids in synaptic signaling. Physiol Rev,
    58. (1979). Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy.
    59. (1981). The effi cacy and safety of nabilone (a synthetic cannabinoid) in the treatment of anxiety.
    60. (2003). The molecular logic of endocannabinoid signaling.
    61. (1982). The prevalence and severity of pain in cancer.
    62. (2003). Therapeutic potential of cannabinoids

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.